Search Videos and More
News
Temple Lung Center | Enrolling Clinical Trials
The Temple Lung Center conducts one of the most comprehensive lung disease clinical trials programs in the country. Our advancements in basic, translational and clinical research are changing lung disease treatment. By pioneering effective therapies, we bring hope to patients with serious and debilitating lung diseases.
Video
Lung Transplantation for COPD Patients
Chronic Obstructive Pulmonary Disease (COPD) is the sixth leading cause of death in the U.S., affecting nearly 16 million adults. Dr. Gerard Criner, Director of the Temple Lung Center, recently joined the Global Forum on Lung Transplantation to explore the role of lung transplantation for COPD.
News
November Quarterly Impact Report: The Temple Healthy Chest Initiative
The American Cancer Society is forecasting more than two million new cases of cancer to be diagnosed in the year 2024. And while the incidence rate is on the rise, cancer-related deaths continue to decline. Early detection is key to producing better outcomes for patients.
Course
Understanding Hemodynamic Profiles in Heart Failure
Managing heart failure requires a comprehensive approach that integrates multiple sources of information, rather than relying on a single data set, says Paul Forfia, MD, co-director of Pulmonary Hypertension, Right Heart Failure & CTEPH Program at Temple University Hospital.
News
Temple Lung Center: Advancing Research in ILD
Interstitial lung diseases (ILD) significantly impact patient morbidity and mortality. As an ILD Center of Excellence, the Temple Lung Center has established comprehensive programs for the evaluation and management of patients with a wide range of ILDs. This includes extensive clinical research and lung transplantation expertise.
Course
Diagnosing the Apical Variant of Hypertrophic Cardiomyopathy
A 60-year-old man with a history of hypertension was admitted to the hospital after three days of a drooping face and right arm weakness. He had no chest pain or shortness of breath, and no prior history of irregular heartbeat. However, his echocardiogram was abnormal, and his high sensitivity troponin level was mildly to moderately elevated. Doctors ordered STAT echocardiogram with saline contrast, but the initial images were perplexing – normal left ventricle function, no evidence of systolic anterior motion, and nothing to suggest an LVOT obstruction.
Video
What is new in 2024 for PE
A comprehensive overview of strategic clinical risk stratification, evidence-based approaches derived from clinical trials and advanced research, and essential insights into the follow-up care of patients post-pulmonary embolism (PE).
Course
Breaking Down Updated Aortic Guidelines for Echocardiographers
In 2022, the American College of Cardiology and the American Heart Association released updated aortic guidelines that synthesized some 20 separate guidelines issued by nearly as many organizations over the previous 12 years.
Course
Technology Update: Redefining Echocardiography Diagnostics and Education with AI, AR, and Beyond
For a photographer or videographer, it’s second nature to use lighting to get a better view of a subject. But few cardiac imagers think about moving light sources within the heart.
Course
2024 GOLD International COPD Conference
Join us on November 11th and 12th for the world’s largest educational symposium on chronic obstructive pulmonary disease (COPD). The upcoming 9th annual GOLD International COPD Conference is once again a two-day event hosted in Philadelphia, Pennsylvania.
Course
An Overview of Common Complications with Structural Heart Disease
The leading treatment option for AS and other structural diseases is transcatheter aortic valve replacement (TAVR). The overall complication rate of TAVR is relatively low -- around 4%. However, patients who experience complications have increased hospital lengths-of-stay and higher one-year mortality rates
Video
Pulmonary Arterial Hypertension and RV Failure
The average time from symptom onset to accurate diagnosis of pulmonary arterial hypertension (PAH) is 2.8 years, and more than half of patients have already progressed to functional class 3 or 4 by the time of diagnosis. Overlapping symptoms and clinical presentations can make it challenging to classify pulmonary hypertension patients correctly.